N/A
Completed N=80
Evaluation of Pharmacist Interventions in Lipid Management for Secondary Prevention
Source: ClinicalTrials.gov NCT06647238 ↗Enrolled (actual)
80
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcomePrimary: Number of Subjects Who Meet Low-density Lipoprotein (LDL) at Goal (<55) — 17; 3 Participants — p=<0.001
Summary
The primary objective of this research project is to compare the effect of pharmacist interventions versus usual care in the implementation of guideline directed lipid lowering therapies for secondary prevention.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Subjects Who Meet Low-density Lipoprotein (LDL) at Goal (<55) |
17; 3 | <0.001 sig |
| SECONDARY Percent Change in Low-density Lipoprotein (LDL) |
-32.9; -6.8 | — |
| SECONDARY Number of Participants With Medications Initiated or Titrated |
10; 3; 18; 1; 6; 0 | — |
| SECONDARY Prevalence of Elevated Lipoprotein(a) |
7; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of coronary artery disease
- low-density lipoprotein (LDL) > 55
- Primary Care Physician at 1 of 6 identified clinics
Exclusion Criteria
- Patients who are no longer an active patient of one of the internal medicine practices
- Patients whose cholesterol is managed by another practice
- Women of childbearing age/potential
- Patients residing in hospice/Long Term Care facilities
- End-stage liver disease
Data sourced from ClinicalTrials.gov (NCT06647238). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.